Duchenne Muscular Dystrophy Treatment, University of Pennsylvania
Summary
The USPTO published patent application US20260109998A1 by The Trustees of the University of Pennsylvania, covering triple-splice mutants of dystrophin or utrophin, viral vectors encoding them, and compositions for treating Duchenne Muscular Dystrophy in human patients. Inventor Hansell Stedman filed the application on September 15, 2025, with CPC classifications C12N 15/86 and C07K 14/4708 indicating biotech/pharmaceutical subject matter. The application is published under Application No. 19328483.
“Described herein are triple-splice mutants of dystrophin or utrophin and methods of use thereof for treating Duchenne Muscular Dystrophy.”
About this source
GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 199 changes logged to date.
What changed
The USPTO has published a new patent application from The Trustees of the University of Pennsylvania covering compositions and methods for treating Duchenne Muscular Dystrophy. The application discloses triple-splice mutants of dystrophin or utrophin, viral vectors comprising nucleic acids encoding these mutants under regulatory element control, and formulated compositions for patient delivery.
Competitors in the DMD therapeutics space should monitor the claims scope and prosecution history of this application to assess potential freedom-to-operate implications. No compliance obligations arise for third parties at this application stage; however, if and when the patent grants, it may affect competitive dynamics in gene therapy approaches to muscular dystrophy treatment.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY
Application US20260109998A1 Kind: A1 Apr 23, 2026
Assignee
The Trustees of the University of Pennsylvania
Inventors
Hansell Stedman
Abstract
Described herein are triple-splice mutants of dystrophin or utrophin and methods of use thereof for treating Duchenne Muscular Dystrophy. Also provided are viral vectors which comprise a nucleic acid encoding a triple-splice mutant dystrophin or utrophin under the control of regulatory elements direct expression thereof. Compositions are also provided which contain such viral vectors formulated for delivery to a human patient.
CPC Classifications
C12N 15/86 C07K 14/4708 C12N 2750/14121 C12N 2750/14122
Filing Date
2025-09-15
Application No.
19328483
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.